Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 5,025 GBp
Change Today +10.00 / 0.20%
Volume 1.4M
SHP On Other Exchanges
Symbol
Exchange
SHP is not on other exchanges.
As of 11:35 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

shire plc (SHP) Snapshot

Open
5,020 GBp
Previous Close
5,015 GBp
Day High
5,060 GBp
Day Low
4,913 GBp
52 Week High
08/4/15 - 5,870 GBp
52 Week Low
10/16/14 - 3,475 GBp
Market Cap
29.7B
Average Volume 10 Days
2.1M
EPS TTM
5.24 GBp
Shares Outstanding
592.0M
EX-Date
09/3/15
P/E TM
14.8x
Dividend
15.20 GBp
Dividend Yield
0.29%
Current Stock Chart for SHIRE PLC (SHP)

shire plc (SHP) Details

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/ VENVANSE/ ELVANSE/ TYVENSE/ ELVANS E VUXEN/ADUVANZ; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides BUCCOLAM for epilepsy treatment; PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist that is used for the treatment of chronic constipation in women. In addition, it offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR and CINRYZE C1 esterase inhibitor for the treatment of hereditary angioedema. Further, the company provides FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; XAGRID that is used for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients; and PLENADREN for the treatment of adrenal insufficiency. Additionally, it licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. The company also focuses on the development of resources projects in various therapeutic areas, including rare diseases, neuroscience, ophthalmics, hematology, and gastrointestinal disorders; and early development projects primarily on rare diseases. Shire plc markets its products through wholesalers and pharmacies. The company has research collaboration with ArmaGen Technologies Inc., Santaris Pharma A/S, and Sangamo. Shire plc was founded in 1986 and is based in Dublin, Ireland.

5,016 Employees
Last Reported Date: 02/24/15
Founded in 1986

shire plc (SHP) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: $3.6M
Compensation as of Fiscal Year 2014.

shire plc (SHP) Key Developments

Shire to Attain Enhanced CINRYZE Manufacturing Flexibility and Capacity

Shire plc announced it has entered into an agreement with Sanquin Blood Supply, providing Shire access to its manufacturing technology and allowing Shire to source additional manufacturers to meet the growing demand for CINRYZE. The specific terms of the agreement are confidential, but involve payments to Sanquin on achievement of certain milestones, including a successful technical transfer to a second source manufacturer. Sanquin will continue to serve as a key partner with Shire to increase global supply of CINRYZE.

Baxalta Incorporated, Shire plc - M&A Call

To discuss proposed combination of Shire plc and Baxalta Incorporated

Shire plc Resolves to Pay an Interim Dividend for the Six Months Ended June 30, 2015, Payable on October 2, 2015

In respect of the six months ended June 30, 2015 the Board of Shire plc resolved to pay an interim dividend of 4.21 cents per ordinary share compared to 3.83 cents per ordinary share paid a year ago. Dividend payments will be made in Pounds Sterling to holders of Ordinary Shares and in US Dollars to holders of ADS's. A dividend of 2.69 pence per Ordinary Share (an increase of 20% compared to 2014: 2.24 pence) and 12.63 cents per ADS (an increase of 10% compared to 2014: 11.49 cents) will be paid on October 2, 2015 to shareholders on the register as at the close of business on September 4, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHP:LN 5,025.00 GBp +10.00

SHP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CSL Ltd A$92.62 AUD -0.13
Eisai Co Ltd ¥8,045 JPY +331.00
Hospira Inc $89.93 USD +0.01
Mylan NV $50.37 USD -1.12
Perrigo Co PLC $185.42 USD -2.77
View Industry Companies
 

Industry Analysis

SHP

Industry Average

Valuation SHP Industry Range
Price/Earnings 14.9x
Price/Sales 7.3x
Price/Book 5.0x
Price/Cash Flow 14.2x
TEV/Sales 7.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.